Akebia Therapeutics (AKBA)
Markets kidney-disease medicines while advancing rare-renal and HIF programs.
Something off on this page? Send us feedback.
Sells Vafseo for dialysis-related anemia and Auryxia for phosphorus control and iron-deficiency anemia, with partner economics outside the United States and a consolidated reportable structure. The business is concentrated in kidney disease, shaped by dialysis-organization protocols, Auryxia generic pressure, and clinical progress in rare kidney programs.
Markets FDA-approved kidney-disease medicines: Vafseo, an oral HIF-PH inhibitor for anemia due to chronic kidney disease in adults on dialysis, and Auryxia, ferric citrate for dialysis-related phosphorus control and iron-deficiency anemia in non-dialysis CKD.
Operates from Cambridge with a focused commercial organization. Vafseo depends on dialysis-organization contracts and prescribing protocols, while Auryxia remains revenue-relevant but faces generic pressure after loss of exclusivity.
Funds development through product sales, partner economics, and licensing relationships covering Vafseo and ferric citrate outside the U.S. The pipeline includes praliciguat, AKB-097, and earlier HIF programs for rare kidney and related renal conditions.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 8, 2026 | WestPark Capital | Initiate | Rating: — | |
| Aug 7, 2026 | Leerink Partners | Downgrade | Target: — | Target: $1 |
| Feb 6, 2026 | Piper Sandler | Reiterate | Rating: —Target: — | Target: $4 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $155.5M · Total debt $54.0M · Total assets $349.7M · Shareholders' equity $25.0M
- Revenue
- $49.1M
- Operating income
- −$6.3M
- Net income
- −$8.9M
No dividends on record.
| Institutions | 39.79% | 110.26M shares | |
|---|---|---|---|
| 177 holders · as of Jun 30, 2026 | |||
| Insiders | 1.57% | 4.34M shares | |
| 13 holders · as of Aug 10, 2026 | |||
| Other | 58.64% | 162.51M shares | |
| remainder | |||
277.11M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 7.21% | 19.99M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.09% | 11.32M | as of Jun 30, 2026 |
AQR Capital Management LLCInstitution | 3.30% | 9.15M | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 2.43% | 6.73M | as of Jun 30, 2026 |
State Street CorpInstitution | 1.95% | 5.39M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 29, 2026 | Erik Ostrowski | officer: SVP, CFO, CBO & Treasurer | −56,019 | $1.11 |
| Mar 4, 2026 | John P. Butler | director, officer: CEO and President | +69,270 | $1.25 |
| Feb 2, 2026 | John P. Butler | director, officer: CEO and President | −341,305 | $1.39 |
| Feb 2, 2026 | Erik Ostrowski | officer: SVP, CFO, CBO & Treasurer | −34,951 | $1.39 |
| Feb 2, 2026 | Carolyn M. Rucci | officer: SVP, Chief Legal Officer | −69,772 | $1.39 |
- Amgen
Incumbent ESAs for dialysis and CKD anemia management
- Teva (ADR)
Generic ferric citrate pressure on Auryxia
- Ardelyx
Non-binder phosphorus control alternative to Auryxia
- Fresenius Medical Care (ADR)
Dialysis-channel phosphate products around Velphoro
- Sanofi (ADR)
Sevelamer phosphate binders against Auryxia
- Johnson & Johnson
Epoetin alfa ESA alternative in CKD anemia
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics | $0.9900 | +1.67% | $251.8M | — | — | 1.1 | −21.4% |
| Amgen | $410.79 | +0.14% | $212.19B | 24.4 | 17.5 | 5.6 | +9.7% |
| Teva (ADR) | $39.60 | +0.28% | $46.66B | 66.8 | 14.1 | 2.7 | −0.8% |
| Ardelyx | $3.60 | −0.83% | $864.6M | — | — | 1.9 | +23.8% |
| Fresenius Medical Care (ADR) | $22.50 | −0.04% | $11.94B | 11.6 | 8.7 | 0.5 | −0.7% |
| Sanofi (ADR) | $42.49 | +0.05% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| Johnson & Johnson | $268.15 | −0.42% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Median | 31.2 | 15.8 | 2.3 | +8.1% |